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Abstract
Background: The French national cancer institute (INCa) conducted a series of studies to assist decision-making in
view of the implementation of organised cervical cancer screening that will be launched in 2018. The programme
will concern all women aged 25–65 and targeted interventions will be developed for underscreened populations.
This is an evolution from an equality-based approach to a step-by-step strategy of equity aiming to tackle health
cancer inequalities that are avoidable and represents unfair differences. Here we present the work of the expert-
group in ethics drafted by INCa to review the ethical issues prior to the programme implementation.
Discussion: We discuss the value of such a strategy and presents reflections with regard to issues of stigmatization,
respect for individual freedom and autonomy. Indeed, the balance has to be found between the search for
beneficence and the potential occurrence of perverse effects, which should be considered with particular attention.
Conclusion: Moving toward an equity-oriented policy under a strategy of proportionate universalism faces a
number of challenges, thus an overview of ethics and social sciences must be an integral part of the process.
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Background
Nationwide organised cervical cancer (CC) screening
will be launched in France in the course of 2018. At
present, health authorities recommend screening with
the Papanicolaou test every three years for women aged
25–65 years, after two first negative tests. As it is a slow
progressing disease, efficient prevention can be obtained
through screening, detection and treatment of precancer-
ous abnormalities. Cervical cancer has a worsened prog-
nosis in case of late diagnosis. In the literature, it is widely
recognised that organised CC screening is more effective
than individual screening in reducing incidence and mor-
tality [1–8]. Most European countries have implemented
population based screening, or plan to do so [9], according
to the European Council Recommendation [10].
In France, screening is therefore opportunistic and
mainly offered through gynaecologists. There is no orga-
nised programme and no individual invitation to the
target population. Even so, screening led to a decrease in
the incidence of cervical cancer (standardised world
standard) of 2.5% per year between 1980 and 2012 in
France [11]. Over the period 2010–2012, the three-year
average overall coverage rate in France was 62.3%, ran-
ging from 41.6 to 72.5% according to geographic loca-
tion [12], but it has been shown that among the 38% of
women who had no Pap-smear, those in vulnerable situ-
ations accounted for a significant proportion [13].
The objective of organised CC screening is to reduce
the incidence and number of deaths by increasing the
coverage rate of screening in the target population. The
French national cancer institute (INCa) conducted a
series of studies to assist decision-making in view of its
implementation [14–16]. These studies first evaluated
the cost-effectiveness of different screening strategies
and then quantified non-participating women, leading to
an accurate assessment of the means that the forthcom-
ing organised programme should deploy. Pilot pro-
grammes were established before generalisation across
the country and have shown that this may improve the
uptake of cervical cancer screening [12]. All together,
* Correspondence: nathalie.duchange@inserm.fr
2Normandie univ, UNICAEN, Inserm U1086, ANTICIPE, 14000 Caen, France
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Darquy et al. BMC Women's Health          (2018) 18:192 
https://doi.org/10.1186/s12905-018-0683-0
the results clearly confirm the importance of the
generalization of CC screening and the need of targeted
actions in order to better reach non-participant
populations.
The proposed organisational framework is a programme
open to all women aged 25–65, with targeted interven-
tions for identified under screened populations. This strat-
egy aims to address socio-economic inequalities found in
the existing organised programmes for cancer screening,
in line with the established priorities of the national
French Cancer Plan 2014–2019.
Taking into account social inequalities in health is es-
sential in the implementation of public health pro-
grammes to avoid loss of opportunity. A universal
approach does not take into account the potential bar-
riers that limit access for some populations. A “gradu-
ated approach” aims to reduce differences between
socio-demographic groups to the extent that comple-
mentary actions are implemented that benefit the popu-
lations that were excluded from them.
For this reason, for the first time in France, the design
of organised screening is thus shifting from a universal
logic, based on equality, to a strategy of proportionate
universalism, a concept according to which health ac-
tions are universal with a scale and intensity that are
proportionate to the level of disadvantage [17]. As
highlighted by Benach et al. [18], there is a distinction
between universal policies that include additional target-
ing of deprived populations, and proportionate univer-
salism that increases benefits along the social gradient.
This is an evolution from an equality-based approach to
a step-by-step strategy of equity aiming to tackle health
cancer inequalities that are avoidable and represent un-
fair differences. The recurrent observation of lower par-
ticipation among deprived populations and minority
groups revealing inequalities in access. This situation
motivates the setting of targeted interventions that are
currently gaining ground in different European countries
(for a review see [19]). Different forms of universalism
and targeting are distinguished and different meanings
are attributed to these concepts [20]. Therefore, it is im-
portant to clarify the design of the program and inter-
ventions especially since each public health programme
has its own particularities and the assessment of the
benefit/risk balance is a decisive factor in justifying the
proposed actions.
In practice, the move towards an equity-oriented pol-
icy within a strategy of proportionate universalism faces
a number of challenges and ethical considerations. This
approach to screening requires the use of social, behav-
ioural or subgroup criteria, with the risk of interfering
with privacy and of stigmatising. Ethical reflection in the
management of organised cancer screening programs
has been introduced since 2009 with the setting of a
dedicated group of experts coordinated by INCa. The
objective is to combine expertise from ethics and social
sciences with that of epidemiologists, public health pol-
icy authorities and practitioners involved in the coordin-
ation and operation of the screening programmes. In
this paper, we present the conclusions of the group who
addressed the issues at stake and analysed the proposed
strategy prior to the implementation of the organised
CC screening programme [21].
Discussion
A public health programme that aims at equity
The efficacy of CC screening in reducing incidence and
mortality is well recognized. Contrarily to other screen-
ing programmes where the balance benefit/risk is de-
bated, It is described as an ‘exemplar population
screening programme’ [22] justifying the commitment of
policy-makers to reduce the loss of opportunity of
women identified as non-participant to individual
screening [13].
Inequalities in health refer to the relationship between
health and social category. There is a close correlation
between socioeconomic status and health: this is called
the “social gradient of health” [23]. Actions designed to
fight social inequalities in health are intended to develop
an integrated approach, in terms of health education,
prevention, screening and access to care [24].
Inequalities in cancer occur at each stage of the life and
health trajectory (exposure to risk factors, access to pre-
vention, participation in screening, quality of care path-
ways, post-cancer conditions) [25]. Inequalities reflect a
cumulative “loss of opportunity” face to the cancer. A
study in France has demonstrated that women’s low social
status is a factor in the occurrence of cervical cancer [13].
It is therefore essential to consider this reality when
implementing public health programmes. The universal
approach is designed for the entire population concerned,
without taking into account the potential barriers that
limit access for some populations. Policies are concerned
with creating equal conditions for health and reducing
health disparities between socio-economic groups. This
notion of health equity is part of a theory of social justice
aimed at the implementation of favourable health condi-
tions for all [26, 27]. From this point of view, the choice
was made to organise the CC screening programme in ac-
cordance with the principle of proportional universalism
[13, 28]. This approach aims at equity in order to limit the
loss of opportunity for those categories of women identi-
fied as non-participants [24].
French organised cervical cancer screening strategy
The programme therefore consists of a global strategy
intended for all women aged 25–65, along with comple-
mentary actions targeted towards the groups of
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non-participating women. The INCa medico-economic
studies [14, 15] have evaluated various possible CC
screening generalisation scenarios, their prioritisation in
terms of participation gains, their ability to reduce in-
equalities and their financial impact. On this basis, the
different targeted actions will be gradually deployed and
evaluated [16].
Targeted strategies are planned according to whether
or not women have been identified as participants in op-
portunistic screening in recent years. The identification
of subgroups of non-participating women will make it
possible to adapt information and awareness raising as
well as to develop specific experimentations (Table 1).
For women over 50 years of age, specific information is
proposed because many of these women wrongly con-
sider that the risk diminishes after age 50 [29]. For
women unaware of their risk, information will be rein-
forced because these populations are under-informed
about risk [30]. For vulnerable populations, it is planned
to send medical and para-medical personnel to offer
screening directly to populations. Lastly, for the category
of high-risk women, specific information will be devel-
oped, as these women are often unfamiliar with the
over-risk category [31].
The ethical issue is the identification of target groups
and the actions that will be offered to them. It will be
necessary to define priorities for action in the light of
the results of the experiments. Choices regarding the al-
location of available resources will have to be made and
justified. This decision-making process requires trans-
parency in the criteria that will guide choices.
Address the risk of stigmatisation in targeted
interventions
Subgroups in which a significant proportion of specific
health problems are observed are often subject to
pre-existing social devaluation. Public health actions
aimed at groups with characteristics negatively perceived
by society raise ethical questions related to the risk of
stigmatisation [32].
Health-related stigma is typically characterised by so-
cial disqualification of individuals and populations who
are identified with particular health problems and behav-
iours related to specific socio-cultural and economic
conditions.
Serious ethical concerns arise through the targeting of
subgroups of populations according to certain character-
istics. For migrant populations for example, the fear of
stigmatisation could prevent the implementation of ac-
tions towards them. When addressing this population in
the name of the principle of beneficence, our recom-
mendation is to recall that the principle of autonomy
must be respected and that screening is not mandatory.
To this end, health professionals must act in accordance
with consent and confidentiality.
Similarly, for precarious or homosexual populations of
women, information could be reinforce through associa-
tions or communities themselves. Meanwhile, training of
health professionals has to be improved.
Targeted actions in public health therefore require the
ethical relevance of the criteria and methods of action
adopted to be called into question [33]. This is referred
to as positive discrimination in the sense that it facili-
tates access to care and tends to reduce health
inequalities.
In France, these questions have emerged in several
public health plans. For example, it was proposed to
suppress the obligatory character of vaccination against
tuberculosis and instead to target it to populations at
risk, mostly disadvantaged people. Targeting is intended
to benefit these precarious populations at risk but in-
volves ethical issues that go beyond medical issues alone,
as it implies specifying the characteristics of a popula-
tion. Tuberculosis is indeed a disease whose occurrence
is encouraged by precarious conditions and migration
from endemic countries, presenting the risk of revealing
a social context at the same time as the disease. The
French national ethics committee has been challenged to
Table 1 Proposed organisation of the French cancer cervical
screening programme
All women 25–65 years of age
Global
Strategy
1. Collective information campaigns and individual invitation
2. Training and diversification of health professionals
(physicians, midwives, nurses)
3. Diffusion of recommendations to professionals,
in particular for the follow-up of pregnant women
(gynaecologists, general practitioners, midwives)
4. Practice harmonisation (standard, recommendations)




Criteria: No Pap-smear recorded for 3 years or more
Women over 50 years of age
(age at which participation
declines)
→ Collective awareness-raising



























both women and health
professionals
→ Information relayed by
associations
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address these issues [34]. The Committee agreed on the
principle of abolition of compulsory vaccination but pro-
duced recommendations as regards targeting these pop-
ulations, in particular respect for the fundamental
freedom of the individuals, including the right to refuse.
It also recommended deploying appropriate information
procedures. The contribution of ethical reflection con-
sists in clearly identifying the values at stake and, above
all, in establishing those which should guide the deci-
sion, in order to assess the reasonableness of public
health activities that may present risks of stigmatisation
towards certain subgroups of the population.
Thus, the risks must be taken into account and
weighed against the expected benefits. Actions with po-
tential risk of stigmatization have to be justified by
evaluating their effective contribution in promoting
health benefits for the people concerned. On another
hand, if the risk of stigmatisation is proven, this may jus-
tify not implementing the action in question. A balance
has to be found between the search for beneficence and
the degree of potential perverse effects; actions to reduce
those have to be sought.
Respect for individual freedom and privacy
There are two approaches in public health, one is the
obligation, as is the case for vaccination, which has re-
cently been reinforced in France [35], and the other is
on the principle of voluntary participation. Participation
in cancer screening is based on respect for autonomy,
meaning that people are asked to decide whether to par-
ticipate in screening. As discussed by Parker et al. [36],
this is not a simple task, particularly when the levels of
benefits and harm are close and prevents experts from
making strong recommendations. As the efficiency of a
programme relies on the level of participation, it is im-
portant that its promotion is balanced with the provision
of an information that includes benefits but also poten-
tial risks and harms so that people can make an in-
formed choice [37].
Making every effort to increase participation is a laud-
able objective when 1) there is a favourable risk-benefit
balance, as in CC screening when the detection of pre-
cancerous lesions has an impact on the incidence of can-
cer, and 2) the underlying issue is to fight against social
inequalities. However, as low participation may call into
question the efficiency of a public health action, vigi-
lance is required as beneficence is not an absolute that
could a priori justify all the actions that may be decided
upon. Thus, it is essential to achieve the desired health
objectives while minimising the degree of intrusion into
the private sphere, and the benefit it generates must be
justified [38, 39]. This may also lead to vigilance on how
targeted actions may potentially conflict with respect for
individual freedom and privacy according to the
principle of autonomy. This calls for an evaluation of the
degree of paternalism that can be justified and accept-
able in the quest for the common good that is health
[40–43].
One way of setting limits on the beneficence impera-
tive and interventionism would be to apply Feinberg’s
proposed distinction between weak (or soft) and strong
(or hard) paternalism [44]. In a weak paternalism, public
authorities seek to elicit the informed consent of people
rather than compel them to act in what appears to be
their best interests. Weak paternalism does not preclude
the concept of promoting autonomy, therefore, as it
gives priority to the informed exercise of the ability to
make a choice [45, 46]. The CC screening programme is
designed with a low paternalism perspective and must
ensure the autonomy of the populations concerned, par-
ticularly those identified as vulnerable.
The target actions aim at reinforcing information and
awareness raising on access to screening within the
framework of respect for autonomy and freedom to
participate.
Conclusion
Organised cervical cancer screening will be launched in
France in 2018 based on proportionate universalism, a
strategy used for the first time for organised cancer
screening in the country. The aim is to provide equal ac-
cess to the test to the whole target population and to
implement complementary actions directed toward
non-participant women previously identified. This will
serve take into account certain needs. The programme,
together with specific actions, will be implemented grad-
ually with regular monitoring to assess their relevance.
An overview of ethics and social sciences are and will be
an integral part of the process, as the balance between
benefits and risks has to be evaluated on an ongoing
basis. The establishment of a proportionate universalism
must take into account the psychosocial reasons for so-
cial inequalities in health and promote actions such as
combating social isolation, restoring the feeling of being
able to exercise control over one’s life, and supporting
individual and community empowerment in order to fa-
cilitate citizen reintegration [47].
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